09:12:30 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-08-07 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning PHO 0.00 NOK
2024-05-23 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-21 Bokslutskommuniké 2023
2023-11-08 Kvartalsrapport 2023-Q3
2023-08-09 Kvartalsrapport 2023-Q2
2023-05-10 Kvartalsrapport 2023-Q1
2023-05-04 Ordinarie utdelning PHO 0.00 NOK
2023-05-03 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2023-02-23 Bokslutskommuniké 2022
2022-11-02 Kvartalsrapport 2022-Q3
2022-08-10 Kvartalsrapport 2022-Q2
2022-05-11 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning PHO 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-23 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-11 Kvartalsrapport 2021-Q2
2021-07-28 Extra Bolagsstämma 2021
2021-05-21 Ordinarie utdelning PHO 0.00 NOK
2021-05-20 Årsstämma 2021
2021-05-19 Kvartalsrapport 2021-Q1
2021-03-03 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-06-11 Ordinarie utdelning PHO 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-07 Kvartalsrapport 2019-Q2
2019-06-19 Extra Bolagsstämma 2019
2019-05-14 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning PHO 0.00 NOK
2019-05-09 Årsstämma 2019
2019-02-27 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-08 Kvartalsrapport 2018-Q2
2018-05-23 Kvartalsrapport 2018-Q1
2018-05-11 Ordinarie utdelning PHO 0.00 NOK
2018-05-09 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-23 Kvartalsrapport 2017-Q1
2017-04-28 Ordinarie utdelning PHO 0.00 NOK
2017-04-27 Årsstämma 2017
2017-02-15 Bokslutskommuniké 2016
2016-11-15 Kvartalsrapport 2016-Q3
2016-08-23 Kvartalsrapport 2016-Q2
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-29 Ordinarie utdelning PHO 0.00 NOK
2016-04-28 Årsstämma 2016
2016-02-11 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-13 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1
2015-05-02 Ordinarie utdelning PHO 0.00 NOK
2015-04-30 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-26 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning PHO 0.00 NOK
2014-05-27 Årsstämma 2014
2014-05-07 Kvartalsrapport 2014-Q1
2014-02-27 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning
2013-05-22 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-28 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-24 Kvartalsrapport 2012-Q2
2012-05-10 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-27 Årsstämma 2011
2011-02-17 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-19 Bokslutskommuniké 2009
2009-11-26 Bonusutdelning

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
Photocure är verksamma inom medicinteknik. Bolaget specialiserar sig inom lösningar för fotodynamisk teknik. Idag används lösningarna för behandling av sjukdomar som föranlett cancer i urinblåsan och HPV. Huvudmarknaderna återfinns inom dermatologi och onkologi, där produkterna används av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1993 och har huvudkontor i Oslo, Norge.
2023-10-07 08:00:00

Press Release - Oslo, Norway, October 7, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated its plan today to unveil the first results of its Hexvix[®] (APL-1706) Phase III clinical trial in China.

The pivotal clinical trial results have been selected as a "late-breaking abstract" for the 43rd Congress of the Société Internationale d'Urologie (SIU) in Istanbul, Turkey, this month. The clinical study results will be presented for the first time in the form of an Oral ePoster on Thursday, October 12, 2023, at 1:45pm local time.

The study is a prospective, self-controlled, multicenter Phase Ⅲ study intended to confirm results from prior clinical trials regarding the safety and detection benefits of blue light cystoscopy (BLC[®]) 4K high definition with Hexvix compared to white light cystoscopy (WLC) in the diagnosis of non-muscle invasive bladder cancer (NMIBC) in a Chinese population. The primary endpoint in the trial is the rate of additional detection of one or more lesions including tumors with stages of carcinoma in situ (CIS), Ta, and T1 by APL-1706 BLC compared to WLC. As previously communicated, t (https://www.photocure.com/news/photocure-partner-asieris-confirms-hexvix-phase-iii-clinical-trial-in-china-meets-endpoint-4602910)he study reached its primary research endpoint (https://www.photocure.com/news/photocure-partner-asieris-confirms-hexvix-phase-iii-clinical-trial-in-china-meets-endpoint-4602910) in August 2023 and the full results are expected to be submitted to Chinese regulators in support of  a new drug application (NDA) in the coming months.

Asieris Pharmaceuticals is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.

In January 2021, Asieris entered into a license agreement with Photocure ASA to obtain the exclusive registration and commercialization rights of Hexvix in mainland China and Taiwan.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than 200 000 deaths in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high recurrence rate with up to 61% in year one and up to 78% over five years.[2] Bladder cancer has the highest lifetime treatment costs per patient of all cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike. 

Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.  Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html
 

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions.
Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and Europe and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer to https://photocure.com/partners/our-partners for further information on our commercial partners.
 

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com